- Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology.
- VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform.
- The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks.
- VERAXA’s Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design.
- AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns.
- The partnership reflects a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.
Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended to strengthen development of the company’s BiTAC(R) oncology platform through AI-enabled target discovery and validation (https://nnw.fm/Yj8dx).
The agreement brings together VERAXA’s antibody engineering capabilities with Ardigen’s expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects for biotechnology and pharmaceutical organizations using AI-driven analytical platforms.
The collaboration illustrates how AI is moving beyond administrative applications into one of the most technically demanding areas of biotechnology: discovering and optimizing new medicines. That trend has accelerated across the pharmaceutical industry during the past two years.
Technology companies are investing heavily in scientific AI models specifically designed for research. Anthropic recently introduced Claude for Science, an initiative focused on computational biology, life sciences, and drug discovery applications, reflecting growing interest in applying large language models and advanced AI systems to scientific research.
Large pharmaceutical companies are also expanding collaborations with specialized AI developers. Earlier this year, Takeda Pharmaceutical, Japan’s leading drug producer, entered a multi-target agreement with AI biotech company Insilico Medicine that could reach up to approximately $1.2 billion in milestone payments and commercial value, combining Takeda’s drug development expertise with Insilico’s generative AI platform for discovering new therapeutics.
Similarly, Boehringer Ingelheim expanded its collaboration with ImmunAI to apply AI-based immune system mapping to immunology research and T-cell biology, another area closely related to modern antibody therapeutics.
These agreements illustrate a broader shift within drug development. Rather than relying solely on traditional laboratory screening, biotechnology companies are increasingly using AI to prioritize targets, analyze multimodal datasets, identify biomarkers, and improve candidate selection before therapies enter expensive clinical development.
For VERAXA in particular, the potential advantages extend beyond simply accelerating discovery. The company’s development strategy centers on its proprietary BiTAC(R)platform, which is designed to create conditionally active antibody therapeutics, including bispecific T-cell engagers (“TCEs”) and antibody-drug conjugates (“ADCs”).
Unlike conventional antibody therapies that recognize a single target, BiTAC(R) molecules employ Boolean “AND-gate” logic. That means activation occurs only when two separate cancer-associated targets are simultaneously expressed on the same cell. The objective is to reduce one of oncology’s persistent challenges: on-target, off-tumor toxicity. Many highly potent cancer therapies have demonstrated encouraging anti-tumor activity but produced unacceptable side effects because healthy tissue also expressed the intended target.
VERAXA believes requiring two targets for activation could widen the therapeutic window by improving tumor selectivity while limiting damage to normal tissue. Selecting the right target combinations, however, presents a significant scientific challenge. Researchers must evaluate enormous amounts of genomic, proteomic and clinical information to identify combinations that maximize efficacy while minimizing toxicity. This is where AI may provide particular value.
According to VERAXA, its collaboration with Ardigen will initially focus on developing AI-enabled computational models capable of identifying synergistic cancer target pairs for future BiTAC(R) therapeutics. Because BiTAC(R) molecules depend on dual-target biology, machine learning can potentially analyze datasets that would be difficult to evaluate using conventional research methods alone.
The company also believes AI could unlock value from decades of existing oncology research. Numerous antibody programs across the industry have demonstrated promising efficacy but ultimately failed because of safety concerns. By analyzing historical clinical and preclinical datasets, AI may help identify new dual-target combinations that preserve therapeutic activity while avoiding the toxicities that limited earlier approaches, potentially bringing previously failed therapies back from the dead.
“We see enormous potential in the application of AI processes to help guide the development strategy of our proprietary BiTAC programs,” commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “Because of the nature of BiTACs, smart cancer target selection and thorough validation from the outset can have a transformative impact on future success rates and product profiles. This collaboration represents a strategic step forward in harnessing the power of AI to bring precision oncology therapies to patients faster” (https://nnw.fm/Z8nUp).
For more information, visit the company’s website at www.veraxa.com.
NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
